There is disclosed a salt of Formula III, a method for manufacturing thereof as well as uses thereof. (Formula III), wherein X is H or OH, Y is H or a cation selected from the group consisting of Li, Na and K, is a single bond or a double bond, and n is 0.5 or 1.

##STR00001##

A method for concentrating and crystallizing fermentable carboxylic acids, salts, and mixtures thereof may involve the use of carboxylic acids that have a defined temperature dependence of the solubility and of the osmotic pressure. The carboxylic acids may be concentrated by a membrane method and subsequently crystallized out by a cooling crystallization and isolated. In some examples, the membrane method may involve nanofiltration, reverse osmosis, and/or membrane distillation for separation into a concentrate and a permeate. Similarly, an apparatus for implementing such methods may include a nanofiltration, reverse osmosis, and/or membrane distillation unit for concentrating the carboxylic acid, and at least one cooling crystallization unit for crystallizing the carboxylic acid.”

A method for concentrating and crystallizing fermentable carboxylic acids, salts, and mixtures thereof may involve the use of carboxylic acids that have a defined temperature dependence of the solubility and of the osmotic pressure. The carboxylic acids may be concentrated by a membrane method and subsequently crystallized out by a cooling crystallization and isolated. In some examples, the membrane method may involve nanofiltration, reverse osmosis, and/or membrane distillation for separation into a concentrate and a permeate. Similarly, an apparatus for implementing such methods may include a nanofiltration, reverse osmosis, and/or membrane distillation unit for concentrating the carboxylic acid, and at least one cooling crystallization unit for crystallizing the carboxylic acid.”

The present invention provides salts consisting of an organocarboxylic acid selected from the group consisting of succinic acid and maleic acid and a compound represented by formula (I)

##STR00001##

and crystals thereat which can be used as bulk materials for pharmaceuticals.

The present invention provides salts consisting of an organocarboxylic acid selected from the group consisting of succinic acid and maleic acid and a compound represented by formula (I)

##STR00001##

and crystals thereat which can be used as bulk materials for pharmaceuticals.

The present invention relates to a process for manufacturing succinic acid as obtained by fermentation, said process exhibiting a high yield in terms of succinic acid crystals recovery and allowing to achieve a final product with a low content of saccharides.

The present invention relates to a process for manufacturing succinic acid as obtained by fermentation, said process exhibiting a high yield in terms of succinic acid crystals recovery and allowing to achieve a final product with a low content of saccharides.

The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

A cholinesterase inhibitor polymorph, wherein specifically disclosed are a octahydroaminoacridine succinate polymorph, a corresponding crystal composition and pharmaceutical composition, and applications thereof. The compound octahydroaminoacridine succinate is used for screening and studying polymorphs, and the discovered polymorphs are appraised and evaluated; crystal forms having better physical and chemical properties are determined for subsequent development and study, and crystal forms having good stability and an excellent therapeutic effect are obtained.